Astria Therapeutics (NASDAQ:ATXS) Stock Price Passes Above 50-Day Moving Average – Time to Sell?

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $4.79 and traded as high as $6.13. Astria Therapeutics shares last traded at $5.86, with a volume of 470,476 shares traded.

Analyst Upgrades and Downgrades

Several research firms recently commented on ATXS. Wedbush reiterated an “outperform” rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, June 13th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $30.00.

Astria Therapeutics Stock Down 0.5%

The firm has a market cap of $330.68 million, a P/E ratio of -3.13 and a beta of 0.39. The company’s 50 day simple moving average is $4.79 and its 200-day simple moving average is $6.41.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Equities research analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATXS. Rhumbline Advisers raised its stake in shares of Astria Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock valued at $556,000 after acquiring an additional 1,381 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Astria Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company’s stock valued at $2,884,000 after buying an additional 8,311 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Astria Therapeutics during the fourth quarter valued at $707,000. Finally, Swiss National Bank grew its holdings in shares of Astria Therapeutics by 13.1% during the fourth quarter. Swiss National Bank now owns 66,600 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 7,700 shares during the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.